|
Synonyms: AGEN-2034 | AGEN2034 | AGEN2034w [6]
Compound class:
Antibody
Comment: Balstilimab (AGEN2034) is an anti-PD-1 checkpoint inhibitor monoclonal antibody. Peptide sequences for the heavy and light chains of balstilimab are claimed in patent US10323091B2 [6], nominally for IgG4 antibody AGEN2034w.
|
| References |
|
1. Bengala E, Santini D, Picone V. (2026)
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. Immunooncol Technol, 29: 101558. [PMID:41502912] |
|
2. Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS et al.. (2024)
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med, 30 (9): 2558-2567. [PMID:38871975] |
|
3. El-Khoueiry AB, Lieu CH, Abou-Alfa GK, Tsimberidou AM, Mahadevan D, Hanna DL, Bockorny B, Wilky BA, Leal A, Stebbing J et al.. (2026)
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma. Liver Cancer, [Epub ahead of print]. [PMID:42131624] |
|
4. Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, Nguyen ATH, Siolas D, Swed B, Hyun J et al.. (2023)
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene, 42 (44): 3252-3259. [PMID:37731056] |
|
5. Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A et al.. (2025)
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer, 13 (12). [PMID:41436232] |
|
6. van Dijk M, Wilson NS, Mundt VA, Ritter G, Wolchok JD, Merghoub T, Zappasodi R, Holmgaard RB, Schaer D, Savitsky DA. (2019)
Anti-PD-1 antibodies and methods of use thereof. Patent number: US10323091B2. Assignee: Ludwig Institute for Cancer Research Ltd Memorial Sloan Kettering Cancer Center, Agenus Inc. Priority date: 01/09/2016. Publication date: 18/06/2019. |
|
7. Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J et al.. (2025)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol, 43 (11): 1358-1368. [PMID:39869830] |